Abstract Library

#4098 A case of functional pancreatic neuroendocrine tumor with hypercalcemia as the main manifestation

Introduction: NEN is a type of rare neoplasm originated from peptidenergic neurons and neuroendocrine cells. Even for functional neuroendocrine tumors, the hormones secreted can be temporally and spatially heterogeneous. Hypercalcemia being a rare clinical manifestation of F-pNEN.

Conference:

Presenting Author: Yingmei T

Authors: Yanping Z, Yingmei T, Jieting D,

Keywords: pancreatic neuroendocrine tumor, functional, parathyroid hormone related peptide,

#3313 Carcinoid heart surgery: Review of outcomes from a single large centre

Introduction: Up to half of patients with carcinoid syndrome develop carcinoid heart disease and valve degeneration can lead to right heart failure. Surgical replacement of affected valves is an effective therapy. Peptide receptor radio-targeted therapy (PRRT) has demonstrated better progression-free survival compared to high dose sandostatin LAR.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Maclean R

Authors: Maclean R, Cope J, Hota S, Mulholland N, Ramage J,

Keywords: PRRT, Lutetium, Lutathera, carcinoid syndrome, valve replacement,

#1646 Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey Among Patients with a Neuroendocrine Tumour

Introduction: Depot somatostatin analogues (SSA) Sandostatin LAR® (SL) and Somatuline Autogel® (SA) injections, are facilitated by a professional home injection service.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Geilvoet W, Feelders R, de Herder W,

Keywords: somatostatin analogues, home injection,

#1149 Optimal Clinical Effect of Sandostatin LAR Treatment for Gastroenteropancreatic (GEP) Carcinoid

Introduction: The incidence of carcinoid is 2/100 000 with a consistent trend grow due to improved diagnosis of these tumors in recent years. There are two peaks of carcinoid incidence – the first between the 15th and 25th years and the second–between the 65th and 75th years

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Robev B, Sergieva S,

Keywords: Carcinoid, Sandostatin LAR,

#810 Pancreatic Neuroendocrine Tumor Presenting in Pregnancy with Severe Hypercalcemia

Introduction: Malignant hypercalcemia secondary to pancreatic neuroendocrine tumor (pNET) is a rare occurrence with no standard management. We report a challenging case of pNET presenting during pregnancy and complicated by severe hypercalcemia.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Assi R

Authors: Assi R, Shamseddine A,

Keywords: pregnancy, pNET, hypercalcemia, embolisation,